Just when we hoped the loudest alarms of the COVID-19 pandemic were behind us, a reminder arrives: the virus isn’t gone, and it’s still evolving. Public health experts have been clear – SARS-CoV-2 continues to mutate, and a new COVID variant NB.1.8.1 has emerged, causing concern and a spike in infections, notably in China. While only a few cases have appeared in the U.S. so far, primarily detected in travelers, it’s a development worth understanding.
The World Health Organization (WHO) has designated NB.1.8.1 as a “variant under monitoring,” which means they’re keeping a close eye on it. It’s moments like these when reliable information feels more important than ever.
Where Did the New COVID Variant NB.1.8.1 Come From?
According to GISAID, a global database tracking virus genetics, the first known cases of the new COVID variant NB.1.8.1 were identified towards the end of April. These initial cases appeared in travelers arriving from a range of countries including China, France, Japan, the Netherlands, Spain, South Korea, Taiwan, and Thailand.
Currently, NB.1.8.1 has become the dominant COVID-19 strain in China. This dominance is reportedly contributing to increases in emergency room visits and hospitalizations there, signaling its potential impact.
Where is the New COVID Variant NB.1.8.1 in the U.S.?
The U.S. Centers for Disease Control and Prevention (CDC) has a surveillance program at several airports where health officials randomly test willing travelers. It was through this program that the new COVID variant NB.1.8.1 was first detected in the U.S., beginning in late March.
Cases of COVID variant NB.1.8.1 US presence have now been reported in a handful of states, including:
- California
- Hawaii
- New York
- Ohio
- Rhode Island
- Virginia
- Washington
So far, the number of detected cases in the U.S. remains small, which is why it doesn’t yet appear prominently on the CDC’s public COVID-19 data tracking site for variants. However, its detection across multiple states indicates it has arrived.
Will the Latest COVID-19 Vaccine Protect Me Against NB.1.8.1?
This is a key question on many minds. The good news is that the new COVID variant NB.1.8.1 is still part of the Omicron family. This relationship means that current vaccines and immunity gained from recent infections should still provide some level of protection, particularly against developing severe disease.
The variant is also on the radar of drug companies. The U.S. Food and Drug Administration (FDA)’s expert vaccine committee met on May 22 to discuss updating the vaccine for the upcoming fall and winter respiratory disease season. During this meeting, they heard data from vaccine makers Pfizer and Moderna regarding experimental vaccines targeting LP.8.1. LP.8.1 is currently a major strain in the U.S. (accounting for over 70% of cases) and is related to both the new COVID variant NB.1.8.1 and JN.1 (the strain targeted by current vaccines). These experimental vaccines reportedly showed slightly stronger protection against both NB.1.8.1 and LP.8.1.
Ultimately, the committee voted to recommend continuing with a JN.1-based vaccine for the updated shot, but did not specify if it should target the LP.8.1 subvariant. The takeaway is that COVID vaccine protection NB.1.8.1 related will likely still be significant with current and upcoming formulations, especially for preventing serious illness.
What Are the Symptoms of COVID Variant NB.1.8.1?
The COVID variant NB.1.8.1 symptoms are similar to those we’ve seen with other COVID-19 strains. These include:
- Sore throat
- Fever
- Cough
- Fatigue
Based on data from other countries where NB.1.8.1 cases have been reported, the variant does not appear to cause more severe disease than its predecessors. However, there’s a catch: genetically, it has changes that might allow it to infect cells more efficiently. This could mean it spreads more easily among people, making it more transmissible. Increased transmissibility is always a concern, even if the severity remains the same, because it can lead to more overall infections.
How Do I Protect Myself Against the New COVID Variant NB.1.8.1?
The strategies to protect from new COVID variant spread, including NB.1.8.1, remain consistent with general COVID-19 prevention measures:
- Vaccination: Staying up-to-date with recommended COVID-19 vaccinations can significantly increase your chances of avoiding severe disease. This is especially crucial for individuals at higher risk, such as older people and those with weakened immune systems.
- Standard Precautions: Consider practicing other well-known preventive measures:
- Wearing a high-quality mask in crowded indoor settings, especially if community transmission is high or you are at higher risk.
- Improving ventilation in indoor spaces.
- Practicing good hand hygiene.
- Testing if you have symptoms and isolating if positive to prevent further spread.
Interestingly, recent announcements regarding vaccination recommendations have added a layer of complexity. U.S. Health Secretary Robert F. Kennedy Jr. stated that the CDC will no longer recommend a yearly shot for healthy children and pregnant women. Additionally, the FDA recently indicated it will not recommend it for healthy adults until vaccine makers conduct more studies on safety and effectiveness in this population. These shifts in guidance highlight the evolving landscape of vaccine recommendations, and individuals should consult with their healthcare providers for personalized advice.
Conclusion: Staying Vigilant and Informed
The emergence of the new COVID variant NB.1.8.1 is a clear signal that SARS-CoV-2 is still an active and evolving virus. While current information suggests that existing vaccines should still offer protection against severe disease from this Omicron family member, and that COVID variant NB.1.8.1 symptoms are similar to previous strains, its potential for increased transmissibility warrants attention.
Staying informed through reliable sources like the CDC and WHO, understanding the current COVID vaccine protection NB.1.8.1 offers, and taking sensible precautions are the best ways to navigate this ongoing situation. The COVID variant NB.1.8.1 US presence is currently limited, but it’s a reminder that the pandemic’s journey isn’t quite over. We must continue to adapt and apply the lessons learned to protect ourselves and our communities.
FAQ
What are the common symptoms of the new COVID variant NB.1.8.1?
Common COVID variant NB.1.8.1 symptoms include sore throat, fever, cough, and fatigue, similar to other COVID-19 strains. It does not currently appear to cause more severe disease.
Is the new COVID variant NB.1.8.1 present in the US?
Yes, a few cases of COVID variant NB.1.8.1 US presence have been detected, primarily in travelers arriving at airports in states like California, Hawaii, and New York.
Do current COVID-19 vaccines protect against NB.1.8.1?
Since NB.1.8.1 is an Omicron subvariant, current COVID vaccine protection NB.1.8.1 related is expected to provide some defense against severe disease, though updated vaccines are continually being evaluated.
Related Articles
COVID-19’s Shadow: Mental Health & Substance Abuse in US Adolescents
Coronavirus Management: Navigating a Complex Path
Oar Health: A New Way to Drink Less or Quit Alcohol
Omada Health Program: Personalized Care, Real Results